NB‐506, an indolocarbazole topoisomerase I inhibitor, binds preferentially to triplex DNA

[1]  J. Chaires,et al.  Sequence and structural selectivity of nucleic acid binding ligands. , 1999, Biochemistry.

[2]  C. Bailly,et al.  Substitution at the F-ring N-imide of the indolocarbazole antitumor drug NB-506 increases the cytotoxicity, DNA binding, and topoisomerase I inhibition activities. , 1999, Journal of medicinal chemistry.

[3]  C. Bailly,et al.  Calories from carbohydrates: energetic contribution of the carbohydrate moiety of rebeccamycin to DNA binding and the effect of its orientation on topoisomerase I inhibition. , 1999, Chemistry & biology.

[4]  J. Trent,et al.  Intercalative G-Tetraplex Stabilization of Telomeric DNA by a Cationic Porphyrin1 , 1999 .

[5]  Y. Pommier,et al.  Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. , 1998, Biochimica et biophysica acta.

[6]  O. Fedoroff,et al.  NMR-Based model of a telomerase-inhibiting compound bound to G-quadruplex DNA. , 1998, Biochemistry.

[7]  R. Wheelhouse,et al.  Cationic Porphyrins as Telomerase Inhibitors: the Interaction of Tetra-(N-methyl-4-pyridyl)porphine with Quadruplex DNA , 1998 .

[8]  R. Shafer.  Stability and structure of model DNA triplexes and quadruplexes and their interactions with small ligands. , 1998, Progress in nucleic acid research and molecular biology.

[9]  N. Saijo.  New chemotherapeutic agents for the treatment of non-small cell lung cancer: the Japanese experience. , 1998, Chest.

[10]  C. Bailly,et al.  DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin. , 1997, Biochemistry.

[11]  H. Kawamoto,et al.  Synthesis of NB-506, A new anticancer agent , 1997 .

[12]  W. Voigt,et al.  Cellular determinants of resistance to indolocarbazole analogue 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13(beta-D-glucopyranosyl)- 5H-indolo[2,3-alpha]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (NB-506), a novel potent topoisomerase I inhibitor, in multidrug-resistant human tumor cells. , 1997, Oncology research.

[13]  J. Chaires,et al.  Energetics of drug-DNA interactions. , 1997, Biopolymers.

[14]  J. Ladbury,et al.  Molecular anchoring of duplex and triplex DNA by disubstituted anthracene-9,10-diones: Calorimetric, UV melting, and competition dialysis studies , 1996 .

[15]  B. Gatto,et al.  Identification of topoisomerase I as the cytotoxic target of the protoberberine alkaloid coralyne. , 1996, Cancer research.

[16]  S. Nishimura,et al.  Antimetastatic Effect of a Novel Indolocarbazole (NB‐506) on IMC‐HM Murine Tumor Cells Metastasized to the Liver , 1996, Japanese journal of cancer research : Gann.

[17]  V. Potaman,et al.  Triple-Helical Nucleic Acids , 1995, Springer New York.

[18]  N. Saijo,et al.  Antitumor activities of a new indolocarbazole substance, NB-506, and establishment of NB-506-resistant cell lines, SBC-3/NB. , 1995, Cancer research.

[19]  S. Nishimura,et al.  Novel indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11-dihydroxy- 13-(beta-D-glucopyranosyl)-5H-indolo[2,3-a]pyrrolo-[3,4-c]carbazole- 5,7(6H)-dione (NB-506): its potent antitumor activities in mice. , 1995, Cancer research.

[20]  S. Nishimura,et al.  Novel antitumor indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11- dihydroxy-13-(beta-D-glucopyranosyl)-5H-indolo[2,3-a]pyrrolo[3,4- c]carbazole-5,7(6H)-dione (NB-506): induction of topoisomerase I-mediated DNA cleavage and mechanisms of cell line-selective cytotoxicity. , 1995, Cancer research.

[21]  G. Zon,et al.  The interaction of intercalators and groove‐binding agents with DNA triple‐helical structures: The influence of ligand structure, DNA backbone modifications and sequence , 1994, Journal of molecular recognition : JMR.

[22]  N. Thuong,et al.  Sequence‐Specific Recognition and Modification of Double‐Helical DNA by Oligonucleotides , 1993 .

[23]  M. Rougée,et al.  Triple helix-specific ligands. , 1992, Science.

[24]  M. Okanishi,et al.  A new antitumor substance BE-13793C, produced by a streptomycete. Taxonomy, fermentation, isolation, structure determination and biological activity. , 1991, The Journal of antibiotics.

[25]  J. Catino,et al.  Production and biological activity of rebeccamycin, a novel antitumor agent. , 1987, The Journal of antibiotics.

[26]  J. Chaires.  Allosteric conversion of Z DNA to an intercalated right-handed conformation by daunomycin. , 1986, The Journal of biological chemistry.

[27]  G. Walker,et al.  Interaction of drugs with Z-DNA: cooperative binding of actinomycin D or actinomine to the left-handed forms of poly(dG-dC).poly(dG-dC) and poly(dG-m5dC).poly(dG-m5dC) reverses the conformation of the helix. , 1985, Biochemistry.

[28]  G. Walker,et al.  Ethidium binding to left-handed (Z) DNAs results in regions of right-handed DNA at the intercalation site. , 1985, Biochemistry.

[29]  A. Rich,et al.  Bromination stabilizes poly(dG-dC) in the Z-DNA form under low-salt conditions. , 1984, Biochemistry.

[30]  D. Crothers,et al.  Studies on interaction of anthracycline antibiotics and deoxyribonucleic acid: equilibrium binding studies on interaction of daunomycin with deoxyribonucleic acid. , 1982, Biochemistry.

[31]  D. Crothers,et al.  Interactions of heteroaromatic compounds with nucleic acids. 1. The influence of heteroatoms and polarizability on the base specificity of intercalating ligands. , 1975, European journal of biochemistry.